Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Lokelma

Lokelma 5 g powder for oral suspension Lokelma 10 g powder for oral suspension · Abschnitt 4.5 · PDF-Seite 4

HOS-133779 · Präparat HOS-097504

As sodium zirconium cyclosilicate is not absorbed or metabolised by the body, and does not meaningfully bind other medicinal products, there are limited effects on other medicinal products. Sodium zirconium cyclosilicate can transiently increase gastric pH by absorbing hydrogen ions and can lead to changes in solubility and absorption kinetics for co-administered medicinal products with pH-dependent bioavailability. In a clinical drug-drug interaction study conducted in healthy subjects co-administration of sodium zirconium cyclosilicate with amlodipine, clopidogrel, atorvastatin, furosemide, glipizide, warfarin, losartan or levothyroxine did not result in clinically meaningful drug- drug interactions. Consistent with co-administration of dabigatran with other gastric acid modifiers, dabigatran Cmax and AUC values were approximately 40% lower when co-administered with sodium zirconium cyclosilicate. No dose adjustments or separation of time of dosing are required for any of these medicinal products. However, sodium zirconium cyclosilicate should be administered at least 2 hours before or 2 hours after oral medicinal products with clinically meaningful gastric pH dependent bioavailability.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): furosemide (HOS-089060) glipizide (HOS-109460) hydrogen (HOS-133780) losartan (HOS-087482) sodium (HOS-109681) zirconium (HOS-133790) atorvastatin (HOS-086304) amlodipine (HOS-086287) dabigatran (HOS-112096) lead (HOS-085592) clopidogrel (HOS-087927) warfarin (HOS-085950) levothyroxine (HOS-086339)